Published in Blood on July 15, 2001
Fates of CD4+ T cells in a tolerant environment depend on timing and place of antigen exposure. Am J Transplant (2011) 1.30
Hematopoietic chimerism and central tolerance created by peripheral-tolerance induction without myeloablative conditioning. J Clin Invest (2003) 1.25
Immunogenicity of pluripotent stem cells and their derivatives. Circ Res (2013) 1.19
Transplantation tolerance through mixed chimerism. Nat Rev Nephrol (2010) 1.17
Transplantation survival is maintained by granzyme B+ regulatory cells and adaptive regulatory T cells. J Immunol (2008) 1.14
New insights into the interactions between T-cell costimulatory blockade and conventional immunosuppressive drugs. Ann Surg (2002) 1.12
Targeting co-stimulatory pathways: transplantation and autoimmunity. Nat Rev Nephrol (2013) 1.11
Retinoic acid in the immune system. Ann N Y Acad Sci (2008) 1.09
OX40 costimulation prevents allograft acceptance induced by CD40-CD40L blockade. J Immunol (2009) 1.01
Co-receptor and co-stimulation blockade for mixed chimerism and tolerance without myelosuppressive conditioning. BMC Immunol (2006) 0.88
The complement dependent cytotoxicity (CDC) immune effector mechanism contributes to anti-CD154 induced immunosuppression. Transplantation (2002) 0.84
Recipient dendritic cells, but not B cells, are required antigen-presenting cells for peripheral alloreactive CD8+ T-cell tolerance. Am J Transplant (2010) 0.83
Mixed chimerism and split tolerance: mechanisms and clinical correlations. Chimerism (2012) 0.83
Differential graft-versus-leukaemia effect by CD28 and CD40 co-stimulatory blockade after graft-versus-host disease prophylaxis. Clin Exp Immunol (2002) 0.83
Manipulating the immune system for anti-tumor responses and transplant tolerance via mixed hematopoietic chimerism. Immunol Rev (2008) 0.83
The role of natural killer T cells in costimulation blockade-based mixed chimerism. Transpl Int (2010) 0.80
Advances in targeting co-inhibitory and co-stimulatory pathways in transplantation settings: the Yin to the Yang of cancer immunotherapy. Immunol Rev (2017) 0.78
Hyperlipidemia Alters Regulatory T Cell Function and Promotes Resistance to Tolerance Induction Through Costimulatory Molecule Blockade. Am J Transplant (2015) 0.77
Signal one and two blockade are both critical for non-myeloablative murine HSCT across a major histocompatibility complex barrier. PLoS One (2013) 0.77
Alloreactive Regulatory T Cells Allow the Generation of Mixed Chimerism and Transplant Tolerance. Front Immunol (2015) 0.76
FTY720 markedly increases alloengraftment but does not eliminate host anti-donor T cells that cause graft rejection on its withdrawal. Biol Blood Marrow Transplant (2012) 0.76
Therapy with monoclonal antibodies by elimination of T-cell subsets in vivo. Nature (1985) 9.62
Visualization of specific B and T lymphocyte interactions in the lymph node. Science (1998) 5.04
"Infectious" transplantation tolerance. Science (1993) 4.98
Reshaping human antibodies for therapy. Nature (1988) 4.82
Mice deficient for the CD40 ligand. Immunity (1994) 4.45
CD59, an LY-6-like protein expressed in human lymphoid cells, regulates the action of the complement membrane attack complex on homologous cells. J Exp Med (1989) 4.19
Impaired resistance to Mycobacterium tuberculosis infection after selective in vivo depletion of L3T4+ and Lyt-2+ T cells. Infect Immun (1987) 3.87
Comparison of the effector functions of human immunoglobulins using a matched set of chimeric antibodies. J Exp Med (1987) 3.82
Immune regulation by CD40 and its ligand GP39. Annu Rev Immunol (1996) 3.56
CD4(+)CD25(+) immune regulatory cells are required for induction of tolerance to alloantigen via costimulatory blockade. J Exp Med (2001) 3.51
Generalized autoimmune disease in interleukin-2-deficient mice is triggered by an uncontrolled activation and proliferation of CD4+ T cells. Eur J Immunol (1995) 3.34
Prevention of collagen-induced arthritis with an antibody to gp39, the ligand for CD40. Science (1993) 3.30
Different roles for L3T4+ and Lyt 2+ T cell subsets in the control of an acute herpes simplex virus infection of the skin and nervous system. J Gen Virol (1987) 3.16
Functional analysis of T lymphocyte subsets in antiviral host defense. J Immunol (1987) 3.11
gp39-CD40 interactions are essential for germinal center formation and the development of B cell memory. J Exp Med (1994) 2.87
Transplantation of ex-vivo culture-expanded parental haploidentical mesenchymal stem cells to promote engraftment in pediatric recipients of unrelated donor umbilical cord blood: results of a phase I-II clinical trial. Bone Marrow Transplant (2008) 2.86
Human protectin (CD59), an 18,000-20,000 MW complement lysis restricting factor, inhibits C5b-8 catalysed insertion of C9 into lipid bilayers. Immunology (1990) 2.77
In vivo CD40-gp39 interactions are essential for thymus-dependent humoral immunity. II. Prolonged suppression of the humoral immune response by an antibody to the ligand for CD40, gp39. J Exp Med (1993) 2.72
Four-year metabolic outcome of a randomised controlled CD3-antibody trial in recent-onset type 1 diabetic patients depends on their age and baseline residual beta cell mass. Diabetologia (2010) 2.65
The regulation of the expression of gp39, the CD40 ligand, on normal and cloned CD4+ T cells. J Immunol (1993) 2.53
Remission induction in non-Hodgkin lymphoma with reshaped human monoclonal antibody CAMPATH-1H. Lancet (1988) 2.51
B-cell growth factor (B-cell growth factor I or B-cell-stimulating factor, provisional 1) is a differentiation factor for resting B cells and may not induce cell growth. Proc Natl Acad Sci U S A (1985) 2.41
CD40-CD40 ligand interactions in experimental allergic encephalomyelitis and multiple sclerosis. Proc Natl Acad Sci U S A (1996) 2.38
The role of CD40 in the regulation of humoral and cell-mediated immunity. Immunol Today (1994) 2.36
Monoclonal antibody treatment exposes three mechanisms underlying the clinical course of multiple sclerosis. Ann Neurol (1999) 2.28
Prope tolerance, perioperative campath 1H, and low-dose cyclosporin monotherapy in renal allograft recipients. Lancet (1998) 2.26
Monoclonal antibodies to promote marrow engraftment and tissue graft tolerance. Nature (1986) 2.25
Factors affecting thymic function after allogeneic hematopoietic stem cell transplantation. Blood (2001) 2.15
Differential effects of the absence of interferon-gamma and IL-4 in acute graft-versus-host disease after allogeneic bone marrow transplantation in mice. J Clin Invest (1998) 2.06
Survival of mouse pancreatic islet allografts in recipients treated with allogeneic small lymphocytes and antibody to CD40 ligand. Proc Natl Acad Sci U S A (1995) 2.06
Activation of the B-cell surface receptor CD40 induces A20, a novel zinc finger protein that inhibits apoptosis. J Biol Chem (1995) 2.05
IL-10 gene expression is controlled by the transcription factors Sp1 and Sp3. J Immunol (2000) 2.04
Generation and large-scale expansion of human inducible regulatory T cells that suppress graft-versus-host disease. Am J Transplant (2011) 1.96
CD40 ligand expression is defective in a subset of patients with common variable immunodeficiency. Proc Natl Acad Sci U S A (1994) 1.94
Letter: T cell-dependent mediator in the immune response. Nature (1973) 1.94
Mast cell degranulation breaks peripheral tolerance. Am J Transplant (2009) 1.94
In vivo CAMPATH-1H prevents graft-versus-host disease following nonmyeloablative stem cell transplantation. Blood (2000) 1.93
Induction of classical transplantation tolerance in the adult. J Exp Med (1989) 1.91
The effect on the growth of BP8 ascites tumour in C3H-C57 or C3H mice of "lymphocyte preparations" from C57 mice injected with BP8 cells and Freund's adjuvant. Br J Cancer (1967) 1.88
The clinical course of experimental autoimmune encephalomyelitis and inflammation is controlled by the expression of CD40 within the central nervous system. J Exp Med (2001) 1.86
Limiting dilution analysis of helper T-cell function. Immunology (1975) 1.82
Removal of T cells from bone marrow for transplantation: a monoclonal antilymphocyte antibody that fixes human complement. Blood (1983) 1.80
Distribution of protectin (CD59), a complement membrane attack inhibitor, in normal human tissues. Lab Invest (1991) 1.79
Induction of tolerance in peripheral T cells with monoclonal antibodies. Eur J Immunol (1990) 1.79
Monocytic origin of foam cells in human atherosclerotic plaques. Atherosclerosis (1984) 1.78
The CAMPATH-1 antigen (CDw52). Tissue Antigens (1990) 1.78
Mechanisms of peripheral tolerance and suppression induced by monoclonal antibodies to CD4 and CD8. Immunol Rev (1996) 1.77
T cell depletion by exposure to Campath-1G in vitro prevents graft-versus-host disease. Bone Marrow Transplant (1994) 1.76
p27kip1 functions as an anergy factor inhibiting interleukin 2 transcription and clonal expansion of alloreactive human and mouse helper T lymphocytes. Nat Med (2000) 1.73
Activation of antigen-specific B cells: role of T cells, cytokines, and antigen in induction of growth and differentiation. Proc Natl Acad Sci U S A (1983) 1.73
Epstein-Barr virus associated B cell lymphoproliferative disorders following bone marrow transplantation. Blood (1988) 1.72
Humanised monoclonal antibody therapy for rheumatoid arthritis. Lancet (1992) 1.72
Identification of murine germinal center B cell subsets defined by the expression of surface isotypes and differentiation antigens. J Immunol (2000) 1.72
The sequential role of lymphotoxin and B cells in the development of splenic follicles. J Exp Med (1998) 1.72
Homeostatic expansion occurs independently of costimulatory signals. J Immunol (2001) 1.70
Pulsed monoclonal antibody treatment and autoimmune thyroid disease in multiple sclerosis. Lancet (1999) 1.69
Long-term survival of skin allografts induced by donor splenocytes and anti-CD154 antibody in thymectomized mice requires CD4(+) T cells, interferon-gamma, and CTLA4. J Clin Invest (1998) 1.67
Phase I study of an engineered aglycosylated humanized CD3 antibody in renal transplant rejection. Transplantation (1999) 1.67
Morbidity and mortality in rheumatoid arthritis patients with prolonged and profound therapy-induced lymphopenia. Arthritis Rheum (2001) 1.67
Treatment of refractory Wegener's granulomatosis with humanized monoclonal antibodies. QJM (1996) 1.66
T cell-dependent mediator in the immune response. II. Physical and biological properties. Immunology (1974) 1.65
The influence of the major histocompatibility complex on the function of T-helper cells in antibody formation. Immunol Rev (1978) 1.64
Human monoclonal IgG isotypes differ in complement activating function at the level of C4 as well as C1q. J Exp Med (1988) 1.63
A phase I/IB trial of murine monoclonal anti-GD2 antibody 14.G2a plus interleukin-2 in children with refractory neuroblastoma: a report of the Children's Cancer Group. Cancer (1997) 1.63
Induction of CD4+ T cell alloantigen-specific hyporesponsiveness by IL-10 and TGF-beta. J Immunol (1999) 1.61
Posttranscriptional regulation of IL-10 gene expression through sequences in the 3'-untranslated region. J Immunol (2000) 1.60
Preliminary evidence from magnetic resonance imaging for reduction in disease activity after lymphocyte depletion in multiple sclerosis. Lancet (1994) 1.59
In vivo transfer of GPI-linked complement restriction factors from erythrocytes to the endothelium. Science (1995) 1.56
Cutting edge: anti-CD154 therapeutic antibodies induce infectious transplantation tolerance. J Immunol (2000) 1.55
Induction of tolerance by monoclonal antibody therapy. Nature (1986) 1.53
Randomized comparison of cyclophosphamide-total body irradiation versus busulfan-cyclophosphamide conditioning in autologous bone marrow transplantation for acute myeloid leukemia. Int J Radiat Oncol Biol Phys (1995) 1.53
Cooperation across the histocompatibility barrier. Nature (1975) 1.51
Cloning of mouse Ox40: a T cell activation marker that may mediate T-B cell interactions. J Immunol (1993) 1.51
CD40 ligand blockade induces CD4+ T cell tolerance and linked suppression. J Immunol (1999) 1.50
Superiority of rapamycin over tacrolimus in preserving nonhuman primate Treg half-life and phenotype after adoptive transfer. Am J Transplant (2014) 1.50
The role of CD40/CD154 interactions in the priming, differentiation, and effector function of helper and cytotoxic T cells. J Leukoc Biol (1998) 1.50
Conditions determining the generation and expression of T helper cells. Immunol Rev (1977) 1.49
Skin allograft rejection by L3/T4+ and Lyt-2+ T cell subsets. Transplantation (1986) 1.49
Antigen-non-specific T-cell factor in B-cell activation. Origin, biological properties and failure to show a relationship to H-2. Immunology (1976) 1.49
A randomized trial comparing prednisone with antithymocyte globulin/prednisone as an initial systemic therapy for moderately severe acute graft-versus-host disease. Biol Blood Marrow Transplant (2000) 1.48
Phenotypical and functional characterization of intrahepatic bile duct cells from common duct ligated mice. J Lab Clin Med (1996) 1.47
Self tolerance is H-2-restricted. Nature (1984) 1.47
Structure of the CAMPATH-1 antigen, a glycosylphosphatidylinositol-anchored glycoprotein which is an exceptionally good target for complement lysis. Biochem J (1993) 1.46
Male donor-derived cells in the brains of female sex-mismatched bone marrow transplant recipients: a Y-chromosome specific in situ hybridization study. J Neuropathol Exp Neurol (1993) 1.46
T cell suppression in transplantation tolerance through linked recognition. J Immunol (1996) 1.45
Regulation of IL-18 (IFN-gamma-inducing factor) gene expression. J Immunol (1997) 1.44
The generation of a humanized, non-mitogenic CD3 monoclonal antibody which retains in vitro immunosuppressive properties. Eur J Immunol (1993) 1.44
Radiotherapy-based conditioning is effective immunosuppression for patients undergoing transplantation with T-cell depleted stem cell grafts for severe aplasia. Cytotherapy (2004) 1.42
Antibody to the ligand of CD40, gp39, blocks the occurrence of the acute and chronic forms of graft-vs-host disease. J Clin Invest (1994) 1.41
Abnormal function of the bone marrow microenvironment in chronic myelogenous leukemia: role of malignant stromal macrophages. Blood (1995) 1.41
Transient increase in symptoms associated with cytokine release in patients with multiple sclerosis. Brain (1996) 1.40
The role of CD4+ T-cell subsets in determining transplantation rejection or tolerance. Immunol Rev (2001) 1.40
Long-term remission of intractable systemic vasculitis with monoclonal antibody therapy. Lancet (1993) 1.40
Infectious tolerance. Curr Opin Immunol (1998) 1.39
T cell-dependent mediator in the immune response. III. The role of non-specific factor (NSF) in the in vitro immune response. Immunology (1975) 1.39
Amplification of natural regulatory immune mechanisms for transplantation tolerance. Transplantation (1996) 1.39